The Australian Nuclear Science and Technology Organisation (ANSTO) is importing technetium-99m (Tc-99m) generators from the United States to supply Australian hospitals, clinics and pharmaceutical suppliers.
Technetium-99m (Tc-99m) is used in hospitals around the world to diagnose a variety of heart, lung and musculoskeletal conditions, as well as cancers. It is the most common nuclear medicine, with global demand estimated to be up to 40 million doses a year, produced by experts with a small network of 11* nuclear reactors worldwide.
Media Statement on nuclear medicine production
ANSTO to reopen to staff tomorrow 18th, April. School holiday workshops, external tours cancelled until Monday.
ANSTO always works with local emergency services, and the Rural Fire Service has advised no risk to ANSTO as a result of the fires in the vicinity of our Lucas Heights campus.
In mid-2018, ANSTO, together with several State and Federal Government agencies, will undertake Australia’s 10th routine transport of spent nuclear fuel assemblies.
ANSTO has recognised the indigenous culture and history that surrounds our campus, with the creation of a Dharawal Mural.
Today the independent nuclear regulator, ARPANSA, has released an Inspection Report in relation to ANSTO’s radiopharmaceutical production facilities.
The ANSTO Nuclear Medicine (ANM) project has achieved a new milestone, reaching practical completion for the Molybdenum-99 (Mo-99) production facility, with contractors handing over the facility to the Australian Nuclear Science and Technology Organisation (ANSTO) to complete the final stages of commissioning.
The man behind Australia’s development and advanced manufacturing of nuclear medicine used in hospitals to diagnose cancers and heart disease has been amongst a number of researchers recognised for their achievements at the ANSTO Awards in Nuclear Science and Technology 2017 presentation dinner.